Cerus Corp

Discover how Cerus Corporation’s INTERCEPT Blood System, now in a new 4‑year deal with France’s Blood Establishment, is reshaping pathogen‑reduced transfusion safety worldwide.

Cerus Corp signs a four‑year deal with France’s national blood service, securing its INTERCEPT platform for platelets and plasma and positioning the company for global expansion in pathogen‑inactivation technology.

Cerus Corporation is a leader in blood transfusion safety, developing cutting-edge technologies to prevent viral, bacterial, and cellular replication, and potentially shaping the future of healthcare.